NeoThetis: Pancreatic
Pancreatic cancer is a malignancy arising from the cells of the pancreas and ranks as the 12th most common cancer worldwide. Despite its relatively low incidence, it is characterized by high mortality and is among the leading causes of cancer-related death globally, ranking third in several developed countries. Cancer initiation and development are characterised by the accumulation of genetic mutations that cause the cancer cells to divide uncontrollably. Examples of genes that have been found to be mutated in patients with pancreatic cancer include KRAS, ALK, and BRCA1, among others. /-approved drugs are available to target pancreatic cancer, depending on the molecular profile of the tumour and the mutated genes present in each patient. One example is olaparib in BRCA-mutated metastatic pancreatic cancer.
Testing for microsatellite instability (MSI) immunotherapy biomarker is also included in this panel, and can expand the treatment opportunities with the -approved immunotherapy drug pembrolizumab for patients with MSI-high status.
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Are you a patient?


Certified laboratories

